Patents Assigned to Sato Pharmaceutical Co., Ltd.
  • Publication number: 20220249440
    Abstract: The present invention is to provide a means for promoting muscle regeneration from muscle damage. According to the present invention, the muscle regeneration from muscle damage is promoted by using a compound having 5-HT2B receptor agonist activity or a salt thereof is used as an active ingredient.
    Type: Application
    Filed: June 25, 2020
    Publication date: August 11, 2022
    Applicants: SATO PHARMACEUTICAL CO., LTD., KEIO UNIVERSITY
    Inventors: Kazumasa OKUBO, Kazuki YUASA, Yoshiki ITOH, Masaya NAKAMURA, Keisuke HORIUCHI
  • Patent number: 11299329
    Abstract: An application container (1) includes a container main body (2); an inner plug member (20); and an impregnation material (30). The inner plug member (20) includes an impregnation material accommodating portion (21), and a valve body accommodating portion (22) which includes a valve seat (22a) on an impregnation material accommodating portion (21) side and a valve body support portion (22b) on a container main body (2) side and in which a valve body (22c) is disposed so as to be movable between the valve seat (22a) and the valve body support portion (22b). A communication groove (50) which forms a gap between the valve body (22c) and the valve body accommodating portion (22) in a state where the valve body (22c) is supported by the valve body support portion (22b) is formed.
    Type: Grant
    Filed: May 27, 2019
    Date of Patent: April 12, 2022
    Assignee: Sato Pharmaceutical Co., Ltd.
    Inventor: Kota Sakata
  • Patent number: 11084792
    Abstract: The present invention provides a method for producing a difluoromethylene compound and an intermediate thereof, which are useful in the field of pharmaceuticals. Specifically provided is a method for producing a difluoromethylene compound, including a step of allowing a compound represented by formula (6): [wherein L1 represents a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a hydroxy lower alkyl group; R1 represents a lower alkyl group, a halogen atom, a halo-lower alkyl group, a cycloalkyl group, a cyano group, or a hydroxy lower alkyl group; and W represents a nitrogen atom or a methine group] to react with a compound represented by formula (7): [wherein R2 represents a lower alkyl group, a halo-lower alkyl group, a cycloalkyl group, a lower alkenyl group, or an aralkyl group; and R3 represents a chlorine atom, a bromine atom, or an iodine atom].
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: August 10, 2021
    Assignee: SATO PHARMACEUTICAL CO., LTD.
    Inventors: Keita Nagai, Toshihiko Ozaki
  • Publication number: 20210220338
    Abstract: The present invention provides a technique that allows a pharmaceutical composition, preferably for external use, containing luliconazole or the like to contain luliconazole or the like at a high concentration, and suppresses the precipitation thereof over time. The present invention uses a polyethylene glycol having an average molecular weight of 380 to 420 represented by a formula HOCH2(CH2OCH2)nCH2OH (where n is an integer), ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone in combination with the luliconazole or the like.
    Type: Application
    Filed: December 17, 2020
    Publication date: July 22, 2021
    Applicant: SATO PHARMACEUTICAL CO., LTD.
    Inventors: Masahiro Ito, Kiyotaka Matsui, Masami Inuma
  • Publication number: 20210046052
    Abstract: The present invention provides a technique that allows a pharmaceutical composition, preferably for external use, containing luliconazole or the like to contain luliconazole or the like at a high concentration, and suppresses the precipitation thereof over time. The present invention uses a polyethylene glycol having an average molecular weight of 380 to 420 represented by a formula HOCH2(CH2OCH2)nCH2OH (where n is an integer), ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone in combination with the luliconazole or the like.
    Type: Application
    Filed: December 30, 2019
    Publication date: February 18, 2021
    Applicant: SATO PHARMACEUTICAL CO., LTD.
    Inventors: Masahiro ITO, Kiyotaka MATSUI, Masami INUMA
  • Patent number: 10898470
    Abstract: The present invention provides a technique that allows a pharmaceutical composition, preferably for external use, containing luliconazole or the like to contain luliconazole or the like at a high concentration, and suppresses the precipitation thereof over time. The present invention uses a polyethylene glycol having an average molecular weight of 380 to 420 represented by a formula HOCH2(CH2OCH2)nCH2OH (where n is an integer), ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone in combination with the luliconazole or the like.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: January 26, 2021
    Assignee: SATO PHARMACEUTICAL CO., LTD.
    Inventors: Masahiro Ito, Kiyotaka Matsui, Masami Inuma
  • Publication number: 20200385820
    Abstract: The present invention has an object to provide a simpler and quicker method for diagnosing tinea, method for detecting a Trichophyton, or method for detecting the Trichophyton gene. Use of at least four kinds of specific primers each designed based on a DNA sequence of the Trichophyton gene makes it possible to simply and quickly detect the Trichophyton gene.
    Type: Application
    Filed: February 15, 2019
    Publication date: December 10, 2020
    Applicants: SATO PHARMACEUTICAL CO., LTD., TEIKYO UNIVERSITY
    Inventors: Koichi MAKIMURA, Kazuo SATOH, Yoshiharu MIYAJIMA
  • Publication number: 20200190038
    Abstract: The present invention provides a method for producing a difluoromethylene compound and an intermediate thereof, which are useful in the field of pharmaceuticals. Specifically provided is a method for producing a difluoromethylene compound, including a step of allowing a compound represented by formula (6): [wherein L1 represents a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a hydroxy lower alkyl group; R1 represents a lower alkyl group, a halogen atom, a halo-lower alkyl group, a cycloalkyl group, a cyano group, or a hydroxy lower alkyl group; and W represents a nitrogen atom or a methine group] to react with a compound represented by formula (7): [wherein R2 represents a lower alkyl group, a halo-lower alkyl group, a cycloalkyl group, a lower alkenyl group, or an aralkyl group; and R3 represents a chlorine atom, a bromine atom, or an iodine atom].
    Type: Application
    Filed: April 27, 2018
    Publication date: June 18, 2020
    Applicant: SATO PHARMACEUTICAL CO., LTD.
    Inventors: Keita NAGAI, Toshihiko OZAKI
  • Patent number: 9650380
    Abstract: A compound having an URAT1 inhibitory activity, and an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: May 16, 2017
    Assignee: SATO PHARMACEUTICAL CO., LTD.
    Inventors: Keita Nagai, Motoaki Baba, Shinichi Fujioka, Koh Nagasawa, Hirobumi Takahashi, Eri Kondoh, Sachie Sogo, Kenichi Tanaka, Yoshiki Itoh
  • Publication number: 20170044158
    Abstract: A compound having an URAT1 inhibitory activity, and an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Applicant: SATO PHARMACEUTICAL CO., LTD.
    Inventors: Keita NAGAI, Motoaki BABA, Shinichi FUJIOKA, Koh NAGASAWA, Hirobumi TAKAHASHI, Eri KONDOH, Sachie SOGO, Kenichi TANAKA, Yoshiki ITOH
  • Patent number: 9512119
    Abstract: The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, the present invention relates to a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: December 6, 2016
    Assignee: SATO PHARMACEUTICAL CO., LTD.
    Inventors: Keita Nagai, Motoaki Baba, Shinichi Fujioka, Koh Nagasawa, Hirobumi Takahashi, Eri Kondoh, Sachie Sogo, Kenichi Tanaka, Yoshiki Itoh
  • Patent number: 9359350
    Abstract: The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: June 7, 2016
    Assignee: SATO PHARMACEUTICAL CO., LTD.
    Inventors: Keita Nagai, Koh Nagasawa, Hirobumi Takahashi, Motoaki Baba, Shinichi Fujioka, Eri Kondoh, Kenichi Tanaka, Yoshiki Itoh
  • Patent number: 9125836
    Abstract: The present invention relates to a film preparation having both rapid solubility and flexibility at the same time. The film preparation is characterized by comprising: an active-ingredient-containing layer comprising an active ingredient, a water-soluble polymer selected from the group consisting of methyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose, and a disintegrating agent; and an active-ingredient-free layer comprising methyl cellulose and/or hydroxypropyl methyl cellulose. It is further characterized in that the amount of the active ingredient is 0.1-75.0 mass % of a total mass of the film preparation and a total content of the active ingredient and the water-soluble polymer in the active-ingredient-containing layer is 15.0-95.0 mass % of a total mass of the active-ingredient-containing layer.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: September 8, 2015
    Assignee: SATO PHARMACEUTICAL CO., LTD.
    Inventors: Toshiro Nagaso, Mitsutoshi Tatara, Toshihito Shimizu
  • Publication number: 20150203490
    Abstract: The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below.
    Type: Application
    Filed: February 11, 2015
    Publication date: July 23, 2015
    Applicant: SATO PHARMACEUTICAL CO., LTD.
    Inventors: Keita NAGAI, Koh NAGASAWA, Hirobumi TAKAHASHI, Motoaki BABA, Shinichi FUJIOKA, Eri KONDOH, Kenichi TANAKA, Yoshiki ITOH
  • Publication number: 20150191463
    Abstract: The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, the present invention relates to a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.
    Type: Application
    Filed: July 26, 2013
    Publication date: July 9, 2015
    Applicant: SATO PHARMACEUTICAL CO., LTD.
    Inventors: Keita Nagai, Motoaki Baba, Shinichi Fujioka, Koh Nagasawa, Hirobumi Takahashi, Eri Kondoh, Sachie Sogo, Kenichi Tanaka, Yoshiki Itoh
  • Patent number: 8987473
    Abstract: The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: March 24, 2015
    Assignee: Sato Pharmaceutical Co., Ltd.
    Inventors: Keita Nagai, Koh Nagasawa, Hirobumi Takahashi, Motoaki Baba, Shinichi Fujioka, Eri Kondoh, Kenichi Tanaka, Yoshiki Itoh
  • Publication number: 20140005221
    Abstract: The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below.
    Type: Application
    Filed: January 30, 2012
    Publication date: January 2, 2014
    Applicant: SATO PHARMACEUTICAL CO., LTD.
    Inventors: Keita Nagai, Koh Nagasawa, Hirobumi Takahashi, Motoaki Baba, Shinichi Fujioka, Eri Kondoh, Kenichi Tanaka, Yoshiki Itoh
  • Publication number: 20100150986
    Abstract: The present invention relates to a film preparation having both rapid solubility and flexibility at the same time. The film preparation is characterized by comprising: an active-ingredient-containing layer comprising an active ingredient, a water-soluble polymer selected from the group consisting of methyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose, and a disintegrating agent; and an active-ingredient-free layer comprising methyl cellulose and/or hydroxypropyl methyl cellulose. It is further characterized in that the amount of the active ingredient is 0.1-75.0 mass % of a total mass of the film preparation and a total content of the active ingredient and the water-soluble polymer in the active-ingredient-containing layer is 15.0-95.0 mass % of a total mass of the active-ingredient-containing layer.
    Type: Application
    Filed: June 7, 2007
    Publication date: June 17, 2010
    Applicant: SATO PHARMACEUTICAL CO., LTD.
    Inventors: Toshiro Nagaso, Mitsutoshi Tatara, Toshihito Shimizu
  • Publication number: 20100055056
    Abstract: The present invention herein provides a compound which promotes drug-permeation into nails. A penetrating promoter comprises, for instance, the following formulas. R1, R2 and R3 are alkyl groups having a carbon number of 1 to 15 and have OH groups at their ends.
    Type: Application
    Filed: September 4, 2008
    Publication date: March 4, 2010
    Applicant: SATO PHARMACEUTICAL CO., LTD.
    Inventors: Masatoshi KATO, Hiroyuki KUSAKABE, Kazuhiro NIMURA, Hiroaki KIMURA, Koh NAGASAWA, Akihiro HASHIGUCHI, Chisato HIROSAWA, Tomohiro TADA
  • Patent number: D628490
    Type: Grant
    Filed: January 14, 2010
    Date of Patent: December 7, 2010
    Assignee: Sato Pharmaceutical Co., Ltd.
    Inventors: Seiichi Sato, Yoshinori Ito